NCT07118137 Memory Deterioration in Alzheimer Disease
| NCT ID | NCT07118137 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Norwegian University of Science and Technology |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-10-15 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2023-10-15 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Semantic AD
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis based on current ICD criteria for AD or MCI . * \>55years. * Norwegian native speaker * Lives at home and not in a health institution Exclusion Criteria: * Patients with severe cognitive impairment that prevents assessment with the selected modalities (planned cut-off: CDR \> 2). * Presence of brain tumors. * History of traumatic brain injury. * History of cranial surgery. * Contraindications to the selected imaging modalities (e.g., 7T MRI or EEG). * Diagnosis of other neurodegenerative diseases such as Parkinson's disease or ALS. 7T MRI contraindications: * Large tattoos close to the head region, permanent makeup or unremoveable piercings * Certain models of pacemakers (if pacemaker implantet, MRI physicist at 7T-lab will be conferred) * Implantet metal in body (clips, stents, prothesis, skrews, plates, teeth etc.)
Contact & Investigator
Axel Sandvig Professor, MD PhD
PRINCIPAL INVESTIGATOR
Norwegian University of Science and Technology (NTNU)
Frequently Asked Questions
Who can join the NCT07118137 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07118137 currently recruiting?
Yes, NCT07118137 is actively recruiting participants. Contact the research team at axel.sandvig@ntnu.no for enrollment information.
Where is the NCT07118137 trial being conducted?
This trial is being conducted at Trondheim, Norway.
Who is sponsoring the NCT07118137 clinical trial?
NCT07118137 is sponsored by Norwegian University of Science and Technology. The principal investigator is Axel Sandvig Professor, MD PhD at Norwegian University of Science and Technology (NTNU). The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.